Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmion -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (9)	9/14/2005 1:32:57 PM
From: tuck	Read Replies (2) \| Respond to of 22

Thanks to Erik for digging this up: >>My opinion is that Celg will get on October 7 an approvable letter from the FDA, pending the Phase III trial to define the role of 5 mg starting dose. The committee was adamant on this point with a 13-2 no vote on the proposed starting dose. This will preclude Rev coming into the market for MDS for a long time. The marketing will the depend on the yet to be submitted NDA for myeloma. << Message 21702668 Hard to compare Vidaza and Revlimid on trial data; would love to hear an oncologist's opinion. My impression is that R is more efficacious, but not as safe. Further, that 5q deletion that R works best with is not so common. Cheers, Tuck